In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.
"The last two years have been very challenging for the company, but as a result of recent progress, I believe we are solidly on a turnaround path and well on our way to building significant shareholder value," stated
Nucleic acids are extremely promising for the treatment of complex and orphan diseases, yet efficient and cell-specific delivery of oligonucleotide therapeutics remains a barrier to clinical progress. Furthermore, as many illnesses are multi-system diseases (i.e., they affect more than one organ or physiological process), treatment will likely not be successful using a singular therapeutic or delivery regimen. Successful treatment may require a customizable approach over the course of care that employs multiple therapeutics, each with a unique biological target, dose, and delivery mechanism. The ability to develop both single- and double-stranded oligonucleotide constructs and combine them with a breadth of delivery technologies will likely provide the greatest chance for clinical success.
Most Popular Stories
- Doctor Who Christmas Episode Begins Production
- HCL America Adding 1,200 IT Jobs
- Medical Mfg. Jobs Coming to Dayton
- Michael Jackson, Freddie Mercury on Previously Unreleased Queen Cut
- Longtime Unemployed to Get Help in Las Vegas
- SpaceX Aims for Predawn Launch on Saturday
- Women Key to Democratic Party: Clinton
- U.S. Chamber Caught Up in Tax Inversion Question
- Feds Won't Say How Many Border Crossers Jailed
- Christie Didn't Order Bridge Shut Down, Feds Say